|
Non-alcoholic Fatty Liver Disease
|
0.380 |
Biomarker
|
disease |
BEFREE |
Elafibranor acts as an agonist of PPAR-α and PPAR-δ and is currently under development for the treatment of NAFLD.
|
31523999 |
2020 |
|
Huntington Disease
|
0.230 |
Biomarker
|
disease |
BEFREE |
PPARδ directly involves in the pathogenesis of HD and treatment with a brain-permeable PPARδ-agonist (KD3010) alleviates its severity in mice.
|
31625071 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, these findings elucidate a novel mechanism by which PPARδ promotes gastric tumorigenesis through interaction with YAP1 and highlights the PPARδ/YAP1/SOX9 axis as a novel therapeutic target in human GC.
|
31796534 |
2020 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
PPARδ knockdown in patient-derived GC cells dramatically reduced SOX9 expression and transcriptional activity, with corresponding decreases in invasion and tumor sphere formation.
|
31796534 |
2020 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Implications: Our discovery of a new model supports a distinct paradigm for PPARδ and a crucial oncogenic function of PPARδ in GC through convergence on YAP1/TEAD signaling.
|
31796534 |
2020 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Implications: Our discovery of a new model supports a distinct paradigm for PPARδ and a crucial oncogenic function of PPARδ in GC through convergence on YAP1/TEAD signaling.
|
31796534 |
2020 |
|
Diabetic Retinopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Downstream, EC transduce these signals and increase their synthesis and release of chemokines such as CCL8 and CXCL10 that regulate leukostasis and other cellular events related to vascular inflammation in DR. Our results indicate that PPARβ/δ inhibition mitigates these upstream (MC) as well as downstream (EC) inflammatory signaling events elicited by metabolic stimuli and inflammatory cytokines.
|
31758977 |
2020 |
|
Myeloid Leukemia, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we verified the upregulation of PPARD in both CML patients-derived CD26 <sup>+</sup> LSCs and donor-derived BCR-ABL1 overexpressed HSCs.
|
31767149 |
2020 |
|
Leukostasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Downstream, EC transduce these signals and increase their synthesis and release of chemokines such as CCL8 and CXCL10 that regulate leukostasis and other cellular events related to vascular inflammation in DR. Our results indicate that PPARβ/δ inhibition mitigates these upstream (MC) as well as downstream (EC) inflammatory signaling events elicited by metabolic stimuli and inflammatory cytokines.
|
31758977 |
2020 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice.
|
31635041 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous investigations have shown that the peroxisome proliferator activated receptor beta/delta (PPAR<beta>/<delta>)-angiopoietin-like protein 4 (ANGPTL4) pathways may be a new pharmacologic target for treatment of obesity.
|
28320596 |
2019 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPARδ) is a ligand-dependent transcription factor involved in fatty acid metabolism, obesity, wound healing, inflammation, and cancer.
|
31239272 |
2019 |
|
Steatohepatitis
|
0.390 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Our data show that PPAR δ inhibition reduces steatosis, inflammation and apoptosis in LPS-related NAFLD damage, in vitro.
|
31839747 |
2019 |
|
Steatohepatitis
|
0.390 |
Biomarker
|
disease |
BEFREE |
PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation.
|
30814493 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.380 |
Biomarker
|
disease |
BEFREE |
These results provide novel insight into the lipolytic actions of PPARδ through autophagy in the liver and highlight its potential beneficial effects in NAFLD.
|
30814493 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.380 |
Biomarker
|
disease |
BEFREE |
In the present study, we aimed to evaluate the role of PPAR δ in LPS associated NAFLD and to investigate the signal transduction pathways underlying PPAR δ treatment in vitro.
|
31839747 |
2019 |
|
Fatty Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation.
|
30814493 |
2019 |
|
Malignant neoplasm of skin
|
0.330 |
Biomarker
|
disease |
BEFREE |
Regulatory mechanisms mediated by peroxisome proliferator-activated receptor-β/δ in skin cancer.
|
31062422 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, PPARδ may be a promising therapeutic target for treatment of insulin resistance in patients with T2DM.
|
30739791 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the effect of PPAR-δ agonists on T2DM-induced cognitive impairment has not been explored.
|
31008686 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results suggest that dual FFA1/PPARδ agonist could be a valuable therapy for type 2 diabetes.
|
30605833 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analyses of diverse populations improves discovery for complex traits.
|
31217584 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPARδ) is a ligand-dependent transcription factor involved in fatty acid metabolism, obesity, wound healing, inflammation, and cancer.
|
31239272 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a nuclear receptor, peroxisome proliferator-activated receptor-δ (PPARδ) plays a critical role in regulating inflammation and cancer, while it is still unclear the mechanism of PPARδ agonist GW501516 on colitis-associated colorectal cancer.
|
30391747 |
2019 |